SCHEMBL1765411

SCHEMBL1765411

O=C(O)c1cc(-c2cc(F)cc(C(F)(F)F)c2)n(-c2ccc(F)c(Cl)c2)n1

nearest known ligand 0.56

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
RPA1 P27694 11/20 0.56
KMT2A Q03164 3/20 0.56
MEN1 O00255 2/20 0.56
ATM Q13315 1/20 0.56
PPP1CA P62136 2/20 0.54
SMN1; SMN2 Q16637 1/20 0.52
MARS1 P56192 2/20 0.52
RXRA P19793 1/20 0.48
RXRB P28702 1/20 0.48
RXRG P48443 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16921430 0.93 RPA1 (0.57) RPA1KMT2AMEN1ATMPPP1CA
SCHEMBL1764956 0.88 PPP1CA (0.64) RPA1KMT2AMEN1ATMPPP1CA
SCHEMBL1526212 0.88 RPA1 (0.61) RPA1KMT2AMEN1ATMPPP1CA
SCHEMBL1764940 0.87 RPA1 (0.60) RPA1KMT2AMEN1ATMPPP1CA
SCHEMBL1765503 0.86 RPA1 (0.61) RPA1KMT2AMEN1ATMPPP1CA
SCHEMBL1765050 0.85 CHRNA7 (0.50) RPA1KMT2AMEN1ATMRXRA
SCHEMBL1765255 0.85 RPA1 (0.61) RPA1KMT2AMEN1ATMPPP1CA
SCHEMBL12597093 0.85 MARS1 (0.59) RPA1KMT2AMEN1ATMPPP1CA
SCHEMBL1765068 0.83 PPP1CA (0.71) RPA1KMT2AMEN1ATMPPP1CA
SCHEMBL3429849 0.82 RXRA (0.42) RXRARXRBRXRG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8399682-B2 Substituted (pyrazolylcarbonyl)imidazolidinones and their use AICURIS GMBH & CO. KG (DE) 2013-03-19 US disclosed
US-8399682-B2 Substituted (pyrazolylcarbonyl)imidazolidinones and their use AICURIS GMBH & CO. KG (DE) 2013-03-19 US disclosed
US-8399682-B2 Substituted (pyrazolylcarbonyl)imidazolidinones and their use AICURIS GMBH & CO. KG (DE) 2013-03-19 US disclosed
US-20110124618-A1 SUBSTITUTED (PYRAZOLYLCARBONYL)IMIDAZOLIDINONES AND THEIR USE AICURIS GMBH & CO. KG (DE) 2011-05-26 US disclosed
US-20110124618-A1 SUBSTITUTED (PYRAZOLYLCARBONYL)IMIDAZOLIDINONES AND THEIR USE AICURIS GMBH & CO. KG (DE) 2011-05-26 US disclosed
US-20110124618-A1 SUBSTITUTED (PYRAZOLYLCARBONYL)IMIDAZOLIDINONES AND THEIR USE AICURIS GMBH & CO. KG (DE) 2011-05-26 US disclosed
CN-101977908-A (pyrazolyl carbonyl) imidazolidinone derivatives for the treatment of retroviral diseases AICURIS GMBH & CO KG 2011-02-16 CN disclosed
WO-2009115213-A1 (PYRAZOLYL CARBONYL)IMIDAZOLIDINONE DERIVATIVES FOR THE TREATMENT OF RETROVIRAL DISEASES AICURIS GMBH & CO. KG (DE) 2009-09-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110124618-A1 SUBSTITUTED (PYRAZOLYLCARBONYL)IMIDAZOLIDINONES AND THEIR USE TPMT, PAICS, THPO RPA1 3978/4885KMT2A 1193/4885MEN1 2360/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.